{"organizations": [], "uuid": "9f13448ec482136493229e196f01d31842fe4e99", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-announces-new-phase-2-data/brief-abbvie-announces-new-phase-2-data-for-upadacitinib-showing-clinical-and-endoscopic-outcomes-in-crohns-disease-at-52-weeks-idUSFWN1Q61BU", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-16T18:54:00.000+02:00", "replies_count": 0, "uuid": "9f13448ec482136493229e196f01d31842fe4e99"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-announces-new-phase-2-data/brief-abbvie-announces-new-phase-2-data-for-upadacitinib-showing-clinical-and-endoscopic-outcomes-in-crohns-disease-at-52-weeks-idUSFWN1Q61BU", "ord_in_thread": 0, "title": "BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks", "locations": [], "entities": {"persons": [{"name": "crohn", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "upadacitinib", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "weeks reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News February 16, 2018 / 4:56 PM / in 8 minutes BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks Reuters Staff 1 Min Read Feb 16 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES NEW PHASE 2 DATA FOR UPADACITINIB SHOWING CLINICAL AND ENDOSCOPIC OUTCOMES IN CROHN‘S DISEASE AT 52 WEEKS * ABBVIE INC - ‍PHASE 3 TRIALS FOR UPADACITINIB IN CROHN‘S DISEASE ARE ONGOING​ * ABBVIE - ‍OVERALL SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH THAT OBSERVED IN OTHER UPADACITINIB STUDIES, WITH NO NEW SAFETY SIGNALS DETECTED​ * ABBVIE - ‍MANY UPADACITINIB-TREATED PATIENTS WHO ACHIEVED CLINICAL RESPONSE§ AFTER 16-WEEK INDUCTION PHASE MAINTAINED RESPONSE AFTER 36-WEEK EXTENSION ​ * ABBVIE INC - ‍ 2 MALIGNANCIES OCCURRED IN 12 MG TWICE-DAILY ARM AND NO DEATHS OCCURRED IN CELEST STUDY​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-16T18:54:00.000+02:00", "crawled": "2018-02-16T19:15:07.001+02:00", "highlightTitle": ""}